Yamamoto, Yutaka http://orcid.org/0000-0001-6147-6828
Yamashiro, Hiroyasu
Schneeweiss, Andreas
Müller, Volkmar
Gluz, Oleg
Klare, Peter
Aktas, Bahriye
Magdolna, Dank
Büdi, László
Pikó, Béla
Mangel, László
Toi, Masakazu
Morita, Satoshi
Ohno, Shinji
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 2 May 2022
Accepted: 24 August 2022
First Online: 3 September 2022
Declarations
:
: Y. Yamamoto has relevant conflicts of interest, as follows; Personal fees from Chugai, AstraZeneca, Kyowa-Kirin, Pfizer, Novartis, Essai, Takeda, Tiho, GE Health Care Japan, Nippon Kayaku, Daiichi-Sankyo, Sysmex, and Lilly. Grants from Chugai, Pfizer, AstraZeneca, Kyowa-Kirin, Daiichi-Sankyo, Nippon Kayaku and Lilly. Y. Yamashiro has relevant conflicts of interest, as follows; Personal Fees(Hornaria) from Chugai, Daiichi-Sankyo, Kyowa Kirin, Eisai, Pfizer, Takeda, Eli Lilly, Takeda, Taiho outside the submitted work. A. Schneeweiss has relevant conflicts of interest, as follows; grants from Celgene, grants from Roche, grants from AbbVie, personal fees (Travel expenses and Honoraria) from Celgene, personal fees (Travel expenses and Honoraria) from Roche,personal fees (Travel expenses and Honoraria) from Pfizer, Honoraria from AstraZeneca, Honoraria from Novartis, Honoraria from MSD, Honoraria from Tesaro, Honoraria from Lilly, Honoraria from Seagen, Honoraria from Gilead, Honoraria from GSK, Honoraria from Bayer, Honoraria from Amgen, Honoraria from Pierre Fabre, outside the submitted work. V. Müller has relevant conflicts of interest, as follows; personal fees from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seagen, GSK, Gilead, personal fees from Genomic Health, Gilead, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, GSK, Gilead, other from I Novartis, Roche, Seagen, Genentech, outside the submitted work. O. Gluz has relevant conflicts of interest, as follows; personal fees from Roche, personal fees from Celgene, outside the submitted work. B. Aktas has relevant conflicts of interest, as follows; grants from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Tesaro, Pharmamar, Promedicis GmbH, Oncowissen.de GmbH, Amgen and Seagen. Honoraria from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD Sharp & Dohme, Tesaro, Pharmamar, Promedicis, Oncowissen.de, Amgen, Seagen. Travel expenses from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Tesaro, Pharmamar, Promedicis GmbH, Oncowissen.de GmbH, Amgen and Seagen. Board of Advisory board of AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Seagen, Tesaro, outside the submitted work. M. Toi has relevant conflicts of interest as follows; grants from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG assoc., Eisai, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi. Lecture honoraria or lecture chair, personal from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, Nippon Kayaku. Advisory board of Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology. Member of the board of directors (no salary) of JBCRG assoc., KBCRN, OOTR, outside the submitted work. S. Morita has relevant conflicts of interest as follows; grants from Eisai, Honoraria from AstraZeneca, Taiho, Chugai, Nippon Boehringer Ingelheim Inc, Bristol Myers Squibb, Novartis, MSD, Kyowa Kirin, Astellas, Pfizer, Ono, Eli Lilly, outside the submitted work. S. Ohno grants from Taiho, grants from Eisai, personal fees from AstraZeneca, personal fees from Chugai, personal fees from Lilly, personal fees from Taiho, personal fees from Pfizer, personal fees from Daiichi-Sankyo, board member of Japan Breast Cancer Research Group, board member of Japan Breast Cancer Society, outside the submitted work. P. Klare, D. Magdolna, L. Büdi, B. Piko, and L. Mangel have nothing to disclose.
: The study was carried out in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan.
: Each study protocol, procedures, and consent forms were approved by the institutional review board of each participating institution in each study. Written informed consent was obtained from all patients in each study. In the process of consenting to each study, patients also agreed to use data for further medical research from other countries.
: Not applicable.